RLAYRelay Therapeutics, Inc.
19.44USD-6.27%Mkt Cap: 4.26B $P/E: —3d ago
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic …
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap4.26B $
Enterprise Value3.44B $
Revenue (TTM)10.35M $
Gross Profit-258.50M $
Net Income (TTM)-276.48M $
Revenue/Share0.0570 USD
Last Price19.44 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees202
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.99
PEG—
EV/EBITDA-11.15
EV/Revenue332.06
P/S417.11
P/B4.84
EPS (TTM)-1.48
EPS (Forward)-1.64
52W Range
3.31090% of range21.27
52W High21.27 USD
52W Low3.310 USD
Profitability
Gross Margin0.00%
Oper. Margin-25949.72%
EBITDA Margin0.00%
Profit Margin-1800.58%
ROE-48.76%
ROA-44.50%
Growth
Revenue Growth-48.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-235.46M $
CapEx (TTM)410.00K $
FCF Margin-1152.10%
FCF Yield-2.80%
Net Debt-880.28M $
Net Debt/EBITDA2.86
Balance Sheet
Debt/Equity0.06
Current Ratio18.27
Quick Ratio17.93
Book Value/Sh4.073 USD
Cash/Share4.157 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.08 USD
Upside (mean)+39.3%
Target Range20.00 USD – 32.00 USD
$20.00+39.3% to mean$32.00
# Analysts13
Ownership
Shares Out.219.14M
Float145.34M
Insiders1.64%
Institutions113.56%
Short Interest
Short Ratio14.0d
Short % Float21.39%
Short % Out.18.37%
Shares Short40.25M
Short (prev mo.)43.04M
Technical
SMA 5018.63 (+4.3%)
SMA 20012.26 (+58.5%)
Beta1.70
S&P 52W Chg18.16%
Avg Vol (30d)2.05M
Avg Vol (10d)2.09M
Technical Indicators
RSI (14)51.0
MACD0.4959
MACD Signal0.5314
MACD Hist.-0.0355
BB Upper20.91 USD
BB Middle19.46 USD
BB Lower18.02 USD
BB Width14.81%
ATR (14)1.014 USD
Vol Ratio (20d)1.18x